CHIR-99021 2HCl(CT99021 dihydrochloride)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
| CAS NO: | 2109414-84-6 |
| 规格: | ≥98% |
包装与价格：
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
产品介绍
理化性质和储存条件
| Molecular Weight (MW) | 501.80 |
|---|
| Formula | C22H19Cl3N8 |
|---|
| CAS No. | 1797989-42-4 |
|---|
| Storage | -20℃ for 3 years in powder form |
|---|
| -80℃ for 2 years in solvent |
| Solubility (In vitro) | DMSO : 60 mg/mL (119.57 mM; Need ultrasonic) |
|---|
| H2O : 7.14 mg/mL (14.23 mM; Need ultrasonic) |
|
| Synonym | CHIR-73911 3HCl; CHIR73911; CHIR 73911 trihydrochloride ; CHIR-911; CHIR911; CHIR 911; CT- 99021; CT-99021; CT- 99021; GSK 3 inhibitor XVI; GSK 3IXV; CHIR99021; CHIR 99021 |
|---|
实验参考方法
| General | Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. |
|---|
| Animal model | Female db/db mice or male ZDF rats with type 2 diabetes |
|---|
| Formulation | Formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose. |
|---|
| Dosages | 48 mg/kg |
|---|
| Administration | Oral gavage |
|---|
| Reference | [1] Ring DB, et al. Diabetes, 2003, 52(3), 588-595. |
|---|
m.cnreagent.com